Eli Lilly Joins Chase for Hot Inflammation Target, Paying $100M for Rights to CSL Drug

February 18, 2026
, 6:00 pm

A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN

CSL Limited retain rights to clazakizumab in end-stage kidney disease. Eli Lilly gets rights to the the IL-6-blocking antibody in other indications that could put it in competition with Novo Nordisk and Novartis.

The post Eli Lilly Joins Chase for Hot Inflammation Target, Paying $100M for Rights to CSL Drug appeared first on MedCity News.

Leave a Replay

4 Health Tech Trends Startups Can’t Ignore, Per an Oak HC/FT Partner

Coral Care Raises $13M to Scale In-Home Pediatric Therapy

Headache Startup Slate Medicines Lands $130M to Bring Novel Migraine Drug Into the Clinic

Sign up for our Newsletter

HealthGility provides healthcare organizations with a solution for patient protected health information disclosure and confidentiality that reduces workloads and ensures the safe and secure sharing of sensitive data between different providers.

Eli Lilly Joins Chase for Hot Inflammation Target, Paying $100M for Rights to CSL Drug

Leave a Replay

Related Posts

4 Health Tech Trends Startups Can’t Ignore, Per an Oak HC/FT Partner

Coral Care Raises $13M to Scale In-Home Pediatric Therapy

Headache Startup Slate Medicines Lands $130M to Bring Novel Migraine Drug Into the Clinic

Follow Us

Sign up for our Newsletter

Our Company

Resources

Connect

© All rights reserved

Contact Us